The U.S. midterms are shaping up as more than a horse race for control of Congress. For investors, a Democratic House would change the near-term policy path on climate and healthcare — two areas that have taken clear hits under the current Republican-led agenda. That does not mean a blue House magically passes a new Green New Deal or Medicare for All. It does mean Democrats would regain the leverage to defend Inflation Reduction Act manufacturing credits, push to restore expired renewable incentives, delay Medicaid cuts, and revive enhanced ACA subsidies through budget fights and debt-ceiling negotiations.

That is the setup. Here are four liquid names we think are worth watching—and likely to outperform if Democrats swing the House and markets price in a more progressive tilt on climate and coverage.

First Solar is the cleanest U.S. solar manufacturing pure play tied to Section 45X advanced manufacturing tax credits. Utility-scale demand remains supported by data-center power needs, but the stock has been trading heavily on policy risk after OBBBA tightened construction and in-service windows for renewable credits. A Democratic House cannot rewrite energy law alone, but it can stop further legislative curtailment and raise the odds that 45X enforcement stays intact. Goldman and others have flagged a House flip as a potential re-rating catalyst for depressed solar equities. Status: high policy beta with real domestic manufacturing leverage.

Enphase was hit harder than utility-scale peers when the Section 25D residential clean-energy credit expired at the end of 2025. U.S. sell-through and installer demand softened sharply into 2026 even as the company kept an international footprint. If House Democrats make restoring homeowner solar and storage incentives a condition in any fiscal deal, ENPH has among the most direct upside in the group. Takeaway: this is a recovery trade on residential policy, not a bet that fundamentals have already bottomed.

Centene is a Medicaid- and Marketplace-focused managed care name. Bernstein and other desks have argued that a Democratic House would prioritize restoring enhanced ACA premium tax credits and delaying Medicaid work requirements and enrollment cuts scheduled for 2027–2028. That is a straight volume-and-risk-pool story for CNC: more covered lives, a healthier mix, and less pressure on medical loss ratios. Pure-play Medicaid exposure makes Centene more policy-sensitive than diversified national insurers.

Hospital operators sit downstream of coverage. When ACA subsidies lapse and Medicaid rolls shrink, uninsured volumes rise and bad debt follows. HCA is a large, liquid hospital name that benefits if Democrats reverse or delay those coverage losses. Analysts note hospital stocks have lagged Medicaid MCOs in pricing in a blue-House scenario — leaving room to catch up if the midterm narrative firms. Takeaway: fewer uninsured patients is the simple catalyst.

Midterms are uncertain. A Democratic House with a Republican Senate and White House still faces vetoes and divided government. Markets can price the scenario early and reverse if polls shift. None of these names are immune to earnings misses, rate moves, or sector rotation.

Still, if Democrats take the House, green manufacturing credits and coverage restoration become live negotiation chips again. $$FSLR ( ▲ 2.12% ), $$ENPH ( ▲ 8.92% ), $$CNC ( ▲ 1.43% ), and $$HCA ( ▼ 1.04% ) are the four names we would watch first for that policy path — likely relative outperformers in that scenario, not guarantees.

A Democratic House would put climate manufacturing credits and coverage restoration back on the table. Watch $$FSLR ( ▲ 2.12% ) and $$ENPH ( ▲ 8.92% ) for renewable-policy beta, and $$CNC ( ▲ 1.43% ) and $$HCA ( ▼ 1.04% ) for the coverage/Medicaid path — names worth watching that are likely to outperform if that scenario plays out.

If you want our top stock picks for 2027 and beyond, click here to upgrade.

Cheers,

Jason Hamlin, Founder, Nicoya Research

This newsletter is for informational and educational purposes only and is not financial advice. I may hold positions in assets discussed. Do your own research and consult a licensed advisor before making investment decisions.